Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
Tonix Pharmaceuticals announced an agreement with a leading group purchasing organization effective May 1, providing coverage for TONMYA to approximately 35 million U.S. commercial lives. This represents roughly 20% of the estimated 177 million commercial lives in the U.S. and marks the first managed care partnership for TONMYA, a first-in-class non-opioid treatment for fibromyalgia.
Key figures
- Drug Name
- TONMYA (cyclobenzaprine HCl sublingual tablets)
- Medicaid coverage pct
- 73%
- Medicaid lives covered
- 55 million
- Commercial lives covered
- 35 million
- Commercial lives coverage pct
- 20%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.